Table 1 HDAC inhibitors (HDI) and their efficacy in reducing NMDA-induced actinification
From: INF2-mediated actin filament reorganization confers intrinsic resilience to neuronal ischemic injury
HDAC inhibited | Treatment (1 h HDI + 5 min NMDA) | % Reduction in actinification (n) |
|---|---|---|
Class I + II | SAHA (1 µM) | 40 ± 6 (5) |
Class I | Santacruzamate (0.3 µM) | 33 ± 3 (3) |
Class I | CI994 (1 µM) | 30 ± 4 (3) |
Class I | FK228 (1 µM) | 36 ± 3 (6) |
Class II | Tubastatin (5 µM) | 21 ± 6 (6) |
Class II | Tubacin (10 µM) | n.d.q. |
Class III | Nicotinamide (2 mM) | n.d.q. |
Class III | Ex527 (2.5, 5, 30, 100 µM) | n.d.q. |
Class III | anti-SRT5 peptides (20 µM) | n.d.q. |
Class III | Suramin (100 µM) | n.d.q. |
